Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | FT536 |
Synonyms | |
Therapy Description |
FT536 comprises iPSC-derived natural killer cells with deletion of CD38 and expressing an IL-15-IL15 receptor fusion and non-cleavable CD16 that have been engineered to express a chimeric antigen receptor (CAR) targeting the alpha3 domain of MICA and MICB, which potentially inhibits growth of MICA/B-expressing tumors (Cancer Res (2021) 81 (13_Supplement): 1591). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
FT536 | FT-536|FT 536 | FT536 comprises iPSC-derived natural killer cells with deletion of CD38 and expressing an IL-15-IL15 receptor fusion and non-cleavable CD16 that have been engineered to express a chimeric antigen receptor (CAR) targeting the alpha3 domain of MICA and MICB, which potentially inhibits growth of MICA/B-expressing tumors (Cancer Res (2021) 81 (13_Supplement): 1591). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06342986 | FT536 Cyclophosphamide + Fludarabine | Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer | Recruiting | USA | 0 |